Member Info for Toukankahmoon

MALTBY

You are kidding aren’t you

We’ve been in multiple discussions with multiple partners for over 2 years now

Yep. I’ve started saving for next June may be. Again, I don’t think they go for a fund raise until the excellent P1b results have pushed the SP up substantially. But they certainly don’t have the cash to push forward on all three fronts.

Cfds

What is your average purchase price and what do you think BP would offer right now to take us over? £1 £2?

The last thing we need right now is a takeover.

And the other b*ll*cks about a NASDAQ listing also makes me spit feathers. It isn’t called a “dual listing” for nothing. To make any sense the capital on NASDAQ would have to be equal to that held on AIM. So instant massive dilution. Yes I know. There are other ways - reverse takeover of a shell company etc. but these are complicated and still result in some dilution. Also it’s no longer clear that a NASDAQ listing is the be all and end all.

We desperately need excellent P1b data to clinch a lucrative licensing deal. Anything else and we get scr*wed.

Tim

I did say that I’d stolen Thorns Pom poms

. . . to satisfy Novartis and precipitate a great licensing deal and all previous false dawns and obfuscations will be forgotten. Barely keeping the lid on this at the moment. One more piece in the jigsaw and it will blow sky high.

Then the issue will be at what price will we take profits😁😁😁

Greeny

Sarcasm is the lowest form of wit

Is it 16-19 or 16-79 year olds

DG

Kind hearted. Sadly mine are too old or too young

BV

Gave a good explanation on another thread.

Straight dox and cleaved dox are the same. But the fact that straight dox enters via a vein and Ava6000 dox “enters” at the tumour micro environment (mostly), makes a huge difference. We don’t understand the full impact of this (though Avacta might), other than of course the astronomic plus which is in essence Precision.

However, unlike Thorn, I’m not sure it matters in the grand plan.

CJ62

I’ve stolen them off him in case I need them tomorrow.

B2H2SL

Not sure I’ll care after a few licences have been signed. I’ll be too busy enjoying the profits to care 🤣🤣🤣🤣

BV

Thanks for explaining

But still not sure then whether two separate treatments or one treatment combining both components is the best approach????

Happy Birthday

What’s your favourite tipple?

So any posts that analyse the risks are drivel?

What a grown up attitude to investing 🤡

Thorn

Fairly obvious to me that 2 molecules cleaved at exactly the same time at the same location are likely to be more effective. And presumably “use up” the same FAP. I.e. half the FAP is used than in the double bag method of treatment.

But just my ha’peth

BV

No. Cleaved ribena has a much better PFCQPR than intravenous undiluted ribena.

Novartis is the chosen partner. Just waiting for excellent P1b results.

Is investor event being zoomed? If so please post link. I can’t find it on Avacta website

Harrogate

Most Christian boys of my age were in their church choir back in the day. Some went on to be altar boys, I didn’t.

. . . but I do see today’s funding as an endorsement of Avacta’s strength. I don’t see SP falling much from here medium term, though no doubt there will be undulations. And there is terrific upside potential. So I have bought a tranche with money extracted from my index trackers. The latter have served me well since I bought in during Covid. And there seems to be wide concerns that they are in for a correction when the tech bubble bursts.

Answers on a post card🤣🤣🤣